Evidence map›Paper›PMID 26391130›Full record

Trial reportJournal of the American Heart Association2015

Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men.

Howard D Sesso, Monik C Jiménez, Lu Wang, Paul M Ridker, Julie E Buring, J Michael Gaziano

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Unveiling the Immune Mechanisms of Hypertension With Single-Cell Transcriptome-Wide Mendelian Randomization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Inflammatory Biomarkers in Hypertension.Current medicinal chemistry · 2025
    Review
  11. Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Frontiers in neurology · 2022
    Article
  16. Observational
  17. Article
  18. Article
  19. Elevated Lipoprotein-Associated Phospholipase AInternational journal of hypertension · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Howard D SessoDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.) Division of Aging, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., J.E.B., M.G.) Department of Epidemiology, Harvard School of Public Health, Boston, MA (H.D.S., J.E.B.).
Monik C JiménezDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.).
Lu WangDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.).
Paul M RidkerDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.).
Julie E BuringDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.) Division of Aging, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., J.E.B., M.G.) Department of Epidemiology, Harvard School of Public Health, Boston, MA (H.D.S., J.E.B.).
J Michael GazianoDivision of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., M.C.J., L.W., P.M.R., J.E.B., M.G.) Division of Aging, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA (H.D.S., J.E.B., M.G.).
Harvard University · USBrigham and Women's Hospital · US

Funding

Examining Racial Disparities in StrokeK01HL124391 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI JIMENEZ, MONIK CARMEN · 2014 to 2018
$761k
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
NCI NIH HHS CA-34944NCI NIH HHS CA-40368NHLBI NIH HHS HL-26490NHLBI NIH HHS HL-34595NHLBI NIH HHS K01 HL124391
6 · The paper itself

Abstract

backgroundSeveral cross-sectional, but few prospective, studies suggest that inflammation may be involved in the development of hypertension. We examined markers of inflammation-high-sensitivity C-reactive protein, interleukin-6, and soluble intercellular adhesion molecule-1-and a marker of fibrinolysis, D-dimer, for their associations with incident hypertension in the Physicians' Health Study. METHODS AND

resultsBaseline blood values and information on hypertension-related risk factors were collected in 1982. Incident hypertension was defined as self-reported initiation of antihypertensive treatment, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg during follow-up. With use of a nested case-control design, 396 cases of incident hypertension and controls free of hypertension were matched 1:1 on age (mean 47.4 years) and follow-up time. In crude matched-pair analyses, the conditional relative risks of hypertension in the second through fourth versus the lowest quartiles for plasma high-sensitivity C-reactive protein were 1.27, 1.73, and 1.81 (Ptrend=0.01); for interleukin-6, 1.22, 1.02, and 1.51 (Ptrend=0.06); for soluble intercellular adhesion molecule-1, 1.00, 0.80, and 1.26 (Ptrend=0.37); and for D-dimer, 1.61, 1.81, and 1.52 (Ptrend=0.46). Multivariable adjustment attenuated the estimates. The multivariable relative risks of hypertension in the second through fourth compared to the lowest quartiles of high-sensitivity C-reactive protein were 1.24, 1.60, and 1.47 (Ptrend=0.20); for interleukin-6, 1.08, 0.92, and 1.36 (Ptrend=0.16); for soluble intercellular adhesion molecule-1, 0.89, 0.79, and 1.18 (Ptrend=0.55); and for D-dimer, 1.48, 1.68, and 1.38 (Ptrend=0.63).

conclusionsElevated plasma inflammatory markers and D-dimer were nonsignificantly associated with a higher risk of hypertension among initially healthy men.

Indexed as

Blood PressureAdultAgedAged, 80 and overAntihypertensive AgentsBiomarkersC-Reactive ProteinDouble-Blind MethodFibrin Fibrinogen Degradation ProductsFibrinolysisHumansHypertensionIncidenceInflammation MediatorsIntercellular Adhesion Molecule-1Interleukin-6Antihypertensive AgentsBiomarkersC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment DICAM1 protein, humanIL6 protein, humanInflammation MediatorsIntercellular Adhesion Molecule-1Interleukin-6blood pressurehypertensioninflammationmenprospective studies

Identifiers

PMID26391130
PMCPMC4599490
OpenAlexW2167770547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.